OnKure Therapeutics (NASDAQ:OKUR) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of OnKure Therapeutics (NASDAQ:OKUR) to a sell rating in a research note released on Saturday.

Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OnKure Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of OnKure Therapeutics in a report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.33.

OnKure Therapeutics Price Performance

OKUR stock opened at $3.39 on Friday. OnKure Therapeutics has a one year low of $1.70 and a one year high of $17.76. The stock has a market cap of $45.87 million, a price-to-earnings ratio of -0.71 and a beta of 0.43. The company has a fifty day moving average price of $2.81 and a two-hundred day moving average price of $2.56.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.09. Research analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC acquired a new stake in OnKure Therapeutics during the first quarter worth approximately $43,000. XTX Topco Ltd acquired a new position in OnKure Therapeutics in the 2nd quarter valued at $25,000. Bailard Inc. bought a new stake in shares of OnKure Therapeutics during the 2nd quarter valued at $34,000. Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics during the 2nd quarter worth $71,000. Finally, Highbridge Capital Management LLC increased its position in shares of OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock worth $1,586,000 after purchasing an additional 224,810 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.